Read More Pharma Industry News Could nomlabofusp become the rare disease catalyst that revalues Larimar? Larimar’s rolling BLA and nomlabofusp data sharpen LRMR’s rare disease biotech story around Friedreich’s ataxia, frataxin and accelerated approval. bySoujanya RaviJuly 1, 2026